ReviewClinical pharmacology and therapeutics2014
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.
Review in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 61 citations in OpenAlex.
- The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.PloS one · 2018Trial
- Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.Scientific reports · 2014Trial
- Precision medicine journey through omics approach.Journal of diabetes and metabolic disorders · 2022Review
- Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.British journal of cancer · 2022Article
- How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.Clinical pharmacology and therapeutics · 2020Article
- Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.Frontiers in pharmacology · 2019Review
- Pharmacogenetic and pharmacogenomic discovery strategies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Germline variants in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Pharmacogenetic testing in oncology: a Brazilian perspective.Clinics (Sao Paulo, Brazil) · 2018Review
- A NovelFrontiers in oncology · 2018Article
- Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.Clinical pharmacology and therapeutics · 2017Review
- Principles and Recommendations for Standardizing the Use of the Next-Generation Sequencing Variant File in Clinical Settings.The Journal of molecular diagnostics : JMD · 2017Article
- Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Bringing a genomic perspective to the safety of drug treatment in oncology.F1000Research · 2017Review
- Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Journal of clinical pharmacology · 2016Review
- Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.Nature reviews. Clinical oncology · 2016Review
- Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Expert review of clinical pharmacology · 2016Review
- Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives.Pharmacogenomics and personalized medicine · 2016Review
- Biotechnology landscape in cancer drug discovery.Future science OA · 2015Article
- Pharmacists in Australian general practice: an opportunity for expertise in precision medicine.Therapeutic advances in drug safety · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
More than 100 medications approved by the US Food and Drug Administration include pharmacogenetic biomarkers in the drug label, many with cancer indications referencing germ line DNA variations. With the advent of next-generation sequencing (NGS) and its rapidly increasing uptake into cancer research and clinical practice, an enormous amount of data to inform documented gene-drug associations will be collected that must be exploited to optimize patient benefit. This review focuses on the implementation of germ line cancer pharmacogenetics in clinical practice. Specifically, it discusses the importance of germ line variation in cancer and the role of NGS in pharmacogenetic discovery and implementation. In the context of a scenario in which massive amounts of NGS-based genetic information will be increasingly available to health stakeholders, this review explores the ongoing debate regarding the threshold of evidence necessary for implementation, provides an overview of recommendations in cancer by professional organizations and regulatory bodies, and discusses limitations of current guidelines and strategies to improve third-party coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.